Evidence map›Paper›PMID 38227162›Full record

ReviewCurrent HIV/AIDS reports2024

More than the Infinite Monkey Theorem: NHP Models in the Development of a Pediatric HIV Cure.

Jairo A Fonseca, Alexis C King, Ann Chahroudi

Abstract readReview
In one paragraph

Review in Current HIV/AIDS reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jairo A FonsecaDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-5456-4694
Alexis C KingDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.ORCID 0000-0001-7479-9546

Funding

Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
Project-003P01HD112217 · NICHD · EMORY UNIVERSITY · PI Ann M Chahroudi · 2023 to 2026
$7.8M
Enhanced latency reversal and reservoir clearance in macaquesR37AI157862 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi · 2021 to 2026
$5.4M
Neurodevelopment after postnatal Zika virus infection in infant macaquesR01NS120182 · NINDS · EMORY UNIVERSITY · PI CHAHROUDI, ANN M, RAPER, JESSICA · 2021 to 2025
$3.7M
NIAID NIH HHS R37 AI157862NIAID NIH HHS UM1 AI164566NICHD NIH HHS P01 HD112217NIH HHS K12 HD000850NIH HHS R37AI157862NINDS NIH HHS R01 NS120182
6 · The paper itself

Abstract

purpose of reviewAn HIV cure that eliminates the viral reservoir or provides viral control without antiretroviral therapy (ART) is an urgent need in children as they face unique challenges, including lifelong ART adherence and the deleterious effects of chronic immune activation. This review highlights the importance of nonhuman primate (NHP) models in developing an HIV cure for children as these models recapitulate the viral pathogenesis and persistence. RECENT

findingsSeveral cure approaches have been explored in infant NHPs, although knowledge gaps remain. Broadly neutralizing antibodies (bNAbs) show promise for controlling viremia and delaying viral rebound after ART interruption but face administration challenges. Adeno-associated virus (AAV) vectors hold the potential for sustained bNAb expression. Therapeutic vaccination induces immune responses against simian retroviruses but has yet to impact the viral reservoir. Combining immunotherapies with latency reversal agents (LRAs) that enhance viral antigen expression should be explored. Current and future cure approaches will require adaptation for the pediatric immune system and unique features of virus persistence, for which NHP models are fundamental to assess their efficacy.

Indexed as

HIV-1HIV InfectionsSimian Immunodeficiency VirusAnimalsAnti-Retroviral AgentsCD4-Positive T-LymphocytesChildHaplorhiniHumansAnti-Retroviral AgentsHIV cureNonhuman primatePediatricReservoir

Identifiers

PMID38227162
PMCPMC10859349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.